Globally, there is a greater emphasis on women's diseases, and more and more innovative drugs and treatments are being introduced to alleviate their suffering. Endometriosis is one of the most common diseases, affecting approximately 170 million women worldwide. With such a large number of women suffering from endometriosis, significant advances in endometriosis treatment are being made by incorporating cutting-edge technologies. As there is a high demand for endometriosis treatment, significant efforts are being made to improve diagnosis methods. Most importantly, women all over the world are becoming more aware of their situation and vocal about it, making growth in this market highly profitable and significant.
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis, Others), Treatment (Pain Medication, Hormone Birth Control, Gonadotropin-releasing Hormone (GnRH) Analogues, Aromatase Inhibitors, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Endometriosis Market size was valued at USD 1.28 USD Billion in 2024.
The Global Endometriosis Market is projected to grow at a CAGR of 4.75% during the forecast period of 2025 to 2032.
The major players operating in the market include Akorn orporated, Pfizer , GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson Private Limited, Bayer AG, Merck & Co. , Prestige Consumer Healthcare , F. Hoffmann La Roche , Bristol Myers Squibb Company, Almirall S.A, Zenomed Healthcare Private Limited, Cadila Pharmaceuticals, Astellas Pharma , Eli Lilly and Company.
The market report covers data from the U.S., Canada ,Mexico, Germany, Italy, France, Spain, UK, Switzerland, Russia, Turkey, Belgium, Netherlands and Rest of Europe, China, India, Japan, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America., UAE, Saudi Arabia, Egypt, South Africa, Israel, Rest of Middle East and Africa.
